<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04211610</url>
  </required_header>
  <id_info>
    <org_study_id>0234-19-SOR</org_study_id>
    <nct_id>NCT04211610</nct_id>
  </id_info>
  <brief_title>Troponin Excretion in Urine in Patients With and Without Chronic Kidney Disease</brief_title>
  <official_title>Troponin Excretion in Urine in Patients With and Without Chronic Kidney Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Soroka University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Soroka University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study, in order to better understand the mechanism of troponin clearance and the&#xD;
      reason for elevated troponin levels in patients with CKD, we aim to evaluate quantitatively&#xD;
      the excretion of troponin in the urine in patients with and without CKD, and with and without&#xD;
      myocardial injury. We will compare urinary troponin levels with blood troponin levels in&#xD;
      these patients. In addition, we will compare the levels of hs-cTnT and hs-cTnI in the&#xD;
      patients' sera and urine.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study population will be screened at the internal wards, the nephrology ward and clinic,&#xD;
      and the intensive cardiac care unit (ICCU) of Soroka Medical Center. It will include patients&#xD;
      who suffer from AMI, patients with CKD with and without any cardiac disease and patients with&#xD;
      no known renal or cardiac disease.&#xD;
&#xD;
      The following information and measurements will be collected:&#xD;
&#xD;
      Demographics - age, sex, weight, height. Past medical history - specifically regarding renal&#xD;
      and cardiac diseases and procedures.&#xD;
&#xD;
      Measured variables in blood serum - troponin T, troponin I, creatinine, total protein,&#xD;
      albumin, myoglobin Measured variables in urine - troponin T, troponin I, creatinine, total&#xD;
      protein, albumin, microalbumin, β2-microglobulin Calculations - GFR (according to MDRD&#xD;
      equation), troponin correction to creatinine (gr troponin per gr creatinine), troponin&#xD;
      excretion ( ), urine albumin/creatinine ratio, urine protein/creatinine ratio.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <target_duration>3 Days</target_duration>
  <primary_outcome>
    <measure>Troponin T in blood vs. urine</measure>
    <time_frame>1 year</time_frame>
    <description>Quantitative measurements of hs-cTnT in blood and urine</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Troponin I in blood vs. urine</measure>
    <time_frame>1 year</time_frame>
    <description>Quantitative measurements of hs-cTnI in blood and urine</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Troponin excretion in urine compared to creatinine</measure>
    <time_frame>1 year</time_frame>
    <description>Comparing urine troponin levels to urine creatinine, albumin, β2-microglobulin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Troponin excretion in urine compared to albumin</measure>
    <time_frame>1 year</time_frame>
    <description>Comparing urine troponin levels to urine albumin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Troponin excretion in urine compared to β2-microglobulin</measure>
    <time_frame>1 year</time_frame>
    <description>Comparing urine troponin levels to urine β2-microglobulin</description>
  </secondary_outcome>
  <number_of_groups>6</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Chronic Kidney Diseases</condition>
  <condition>Acute Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>Group 1 - Healthy subjects without any evidence of cardiac o</arm_group_label>
    <description>Inclusion criteria:&#xD;
Normal serum troponin (below the 99th percentile)&#xD;
GFR 60ml/min&#xD;
Proteinuria &lt;1gr/gr creatinine&#xD;
Blood and urine samples will be collected for troponin and other measures.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2 - Subjects with acute myocardial infarction and norm</arm_group_label>
    <description>Inclusion criteria:&#xD;
At least one measurements of serum troponin above the 99th percentile, with either a rise or fall in cardiac troponin levels.&#xD;
GFR 60ml/min/1.73m2&#xD;
Blood and urine samples will be collected for troponin and other measures.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3 - Subjects with acute myocardial infarction and decr</arm_group_label>
    <description>Inclusion criteria - Group 3a:&#xD;
At least one measurements of serum troponin above the 99th percentile, with either a rise or fall in cardiac troponin levels.&#xD;
30 GFR &lt;60ml/min/1.73m2&#xD;
Inclusion criteria - Group 3b:&#xD;
At least one measurements of serum troponin above the 99th percentile, with either a rise or fall in cardiac troponin levels.&#xD;
GFR &lt;30ml/min/1.73m2&#xD;
Blood and urine samples will be collected for troponin and other measures.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4 - Subjects with decreased GFR but without any eviden</arm_group_label>
    <description>Inclusion criteria - Group 4a:&#xD;
Normal serum troponin (below the 99th percentile)&#xD;
No known past medical history of any cardiac disease and/or procedure.&#xD;
30 GFR &lt;60ml/min/1.73m2&#xD;
Inclusion criteria - Group 4b:&#xD;
Normal serum troponin (below the 99th percentile)&#xD;
No known past medical history of any cardiac disease and/or procedure.&#xD;
GFR &lt;30ml/min/1.73m2&#xD;
Blood and urine samples will be collected for troponin and other measures.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 5 - Subjects with chronic myocardial injury and normal</arm_group_label>
    <description>Inclusion criteria:&#xD;
At least one measurements of serum troponin above the 99th percentile, with neither a rise nor fall in cardiac troponin levels.&#xD;
GFR 60ml/min/1.73m2&#xD;
Blood and urine samples will be collected for troponin and other measures.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 6 - patients on RRT</arm_group_label>
    <description>Inclusion criteria:&#xD;
a. Patients who are dependent on renal replacement therapy, including hemodialysis, peritoneal or hemodiafiltration.&#xD;
Blood and urine samples will be collected for troponin and other measures.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Blood and urine sampling</intervention_name>
    <description>Blood tests - hs-cTnT, hs-cTnI, complete metabolic panel including urea, creatinine, albumin and myoglobin&#xD;
Urine tests - hs-cTnT, hs-cTnI, urea, creatinine, albumin, total protein, β2-microglobulin.</description>
    <arm_group_label>Group 1 - Healthy subjects without any evidence of cardiac o</arm_group_label>
    <arm_group_label>Group 2 - Subjects with acute myocardial infarction and norm</arm_group_label>
    <arm_group_label>Group 3 - Subjects with acute myocardial infarction and decr</arm_group_label>
    <arm_group_label>Group 4 - Subjects with decreased GFR but without any eviden</arm_group_label>
    <arm_group_label>Group 5 - Subjects with chronic myocardial injury and normal</arm_group_label>
    <arm_group_label>Group 6 - patients on RRT</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood and urine samples will be collected from each patient&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The study population will be screened at the internal wards, the nephrology ward and&#xD;
        clinic, and the intensive cardiac care unit (ICCU) of Soroka Medical Center. It will&#xD;
        include patients who suffer from AMI, patients with CKD with and without any cardiac&#xD;
        disease and patients with no known renal or cardiac disease. The study population will be&#xD;
        enrolled according to the above inclusion and exclusion criteria.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients who are able to give informed consent.&#xD;
&#xD;
          2. Age ≥ 18&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pregnant women&#xD;
&#xD;
          2. Patients after kidney transplantation.&#xD;
&#xD;
          3. Patients after heart transplantation.&#xD;
&#xD;
          4. Anuric patients.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yosef Haviv, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Soroka UMC, Nephrology Department, Director</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yasmeen Abu Fraiha, MD</last_name>
    <phone>+972505607045</phone>
    <email>yasmeenaf23@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Roi Weistreich, MD</last_name>
    <phone>+9725260707152</phone>
    <email>roiwest@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Soroka Medical Center</name>
      <address>
        <city>Be'er Sheva</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yasmeen Abu Fraiha, MD</last_name>
      <email>yasmeenaf23@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <reference>
    <citation>Twerenbold R, Wildi K, Jaeger C, Gimenez MR, Reiter M, Reichlin T, Walukiewicz A, Gugala M, Krivoshei L, Marti N, Moreno Weidmann Z, Hillinger P, Puelacher C, Rentsch K, Honegger U, Schumacher C, Zurbriggen F, Freese M, Stelzig C, Campodarve I, Bassetti S, Osswald S, Mueller C. Optimal Cutoff Levels of More Sensitive Cardiac Troponin Assays for the Early Diagnosis of Myocardial Infarction in Patients With Renal Dysfunction. Circulation. 2015 Jun 9;131(23):2041-50. doi: 10.1161/CIRCULATIONAHA.114.014245. Epub 2015 May 6.</citation>
    <PMID>25948542</PMID>
  </reference>
  <reference>
    <citation>Freda BJ, Tang WH, Van Lente F, Peacock WF, Francis GS. Cardiac troponins in renal insufficiency: review and clinical implications. J Am Coll Cardiol. 2002 Dec 18;40(12):2065-71. Review.</citation>
    <PMID>12505215</PMID>
  </reference>
  <reference>
    <citation>Kanderian AS, Francis GS. Cardiac troponins and chronic kidney disease. Kidney Int. 2006 Apr;69(7):1112-4.</citation>
    <PMID>16531987</PMID>
  </reference>
  <reference>
    <citation>Ziebig R, Lun A, Hocher B, Priem F, Altermann C, Asmus G, Kern H, Krause R, Lorenz B, Möbes R, Sinha P. Renal elimination of troponin T and troponin I. Clin Chem. 2003 Jul;49(7):1191-3.</citation>
    <PMID>12816921</PMID>
  </reference>
  <reference>
    <citation>Petra, P., Tomo, S., Ingrid, P., Jurica, V., Andrea, R., &amp; Sonja, P. Urine Concentrations of High-Sensitivity Cardiac Troponin I in Healthy Adults - Preliminary Reference Intervals. Acta Med Croatica , 461-465, 2018</citation>
  </reference>
  <reference>
    <citation>Petra, P., Tomo, S., Ingrid, P., Ana, S., Matija, B., &amp; Sonja, P. Urine High-Sensitive Troponin I Measuring in Patients with Hypertension. Signa Vitae , 13(SUPPL 3): 62-64, 2017</citation>
  </reference>
  <reference>
    <citation>Fridén V, Starnberg K, Muslimovic A, Ricksten SE, Bjurman C, Forsgard N, Wickman A, Hammarsten O. Clearance of cardiac troponin T with and without kidney function. Clin Biochem. 2017 Jun;50(9):468-474. doi: 10.1016/j.clinbiochem.2017.02.007. Epub 2017 Feb 11.</citation>
    <PMID>28193484</PMID>
  </reference>
  <reference>
    <citation>Thygesen K, Alpert JS, Jaffe AS, Chaitman BR, Bax JJ, Morrow DA, White HD; Executive Group on behalf of the Joint European Society of Cardiology (ESC)/American College of Cardiology (ACC)/American Heart Association (AHA)/World Heart Federation (WHF) Task Force for the Universal Definition of Myocardial Infarction. Fourth Universal Definition of Myocardial Infarction (2018). Glob Heart. 2018 Dec;13(4):305-338. doi: 10.1016/j.gheart.2018.08.004. Epub 2018 Aug 25. Review.</citation>
    <PMID>30154043</PMID>
  </reference>
  <reference>
    <citation>Dubin RF, Li Y, He J, Jaar BG, Kallem R, Lash JP, Makos G, Rosas SE, Soliman EZ, Townsend RR, Yang W, Go AS, Keane M, Defilippi C, Mishra R, Wolf M, Shlipak MG; CRIC Study Investigators. Predictors of high sensitivity cardiac troponin T in chronic kidney disease patients: a cross-sectional study in the chronic renal insufficiency cohort (CRIC). BMC Nephrol. 2013 Oct 22;14:229. doi: 10.1186/1471-2369-14-229.</citation>
    <PMID>24148285</PMID>
  </reference>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>December 23, 2019</study_first_submitted>
  <study_first_submitted_qc>December 23, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 26, 2019</study_first_posted>
  <last_update_submitted>May 9, 2021</last_update_submitted>
  <last_update_submitted_qc>May 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Soroka University Medical Center</investigator_affiliation>
    <investigator_full_name>Yasmeen Abu Fraiha</investigator_full_name>
    <investigator_title>Internal Medicine Resident, Internal Medicine Department B</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

